The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl
- PMID: 19217274
- DOI: 10.1016/j.ceb.2009.01.014
The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl
Abstract
As an inhibitor of the tyrosine kinase activity of the BCR-Abl oncoprotein, imatinib sets a new paradigm for the treatment of cancer with molecularly targeted therapies. Subsequent structural studies have provided in depth knowledge of how this antileukaemia drug interacts with the catalytic site of the enzyme and allowed the rationalisation of mechanisms of drug-resistance which can lead to patient relapse. This understanding has facilitated the design of new inhibitors of BCR-Abl, as well as the discovery of inhibitors of many other kinases. As structural information accumulates for more of the 518 kinases encoded within the human genome, the design of many more highly selective, well-tolerated kinase inhibitors should be possible.
Similar articles
-
Imatinib as a paradigm of targeted therapies.Adv Cancer Res. 2004;91:1-30. doi: 10.1016/S0065-230X(04)91001-9. Adv Cancer Res. 2004. PMID: 15327887 Review.
-
Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia as a model of rational drug design in cancer.Expert Rev Hematol. 2010 Feb;3(1):45-56. doi: 10.1586/ehm.09.66. Expert Rev Hematol. 2010. PMID: 21082933 Review.
-
Inhibitors of Bcr-abl... breaking new ground again.Nat Chem Biol. 2006 Feb;2(2):63-4. doi: 10.1038/nchembio0206-63. Nat Chem Biol. 2006. PMID: 16421581 No abstract available.
-
Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors.Curr Opin Drug Discov Devel. 2004 Sep;7(5):639-48. Curr Opin Drug Discov Devel. 2004. PMID: 15503866 Review.
-
Lessons learned from the development of imatinib.Leuk Res. 2004 May;28 Suppl 1:S29-38. doi: 10.1016/j.leukres.2003.10.002. Leuk Res. 2004. PMID: 15036939 Review. No abstract available.
Cited by
-
Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs.J Mol Biol. 2022 Sep 15;434(17):167569. doi: 10.1016/j.jmb.2022.167569. Epub 2022 Apr 1. J Mol Biol. 2022. PMID: 35378118 Free PMC article. Review.
-
BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia.Pharmaceutics. 2022 Jan 17;14(1):215. doi: 10.3390/pharmaceutics14010215. Pharmaceutics. 2022. PMID: 35057108 Free PMC article. Review.
-
Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment.Clin Cancer Res. 2022 Apr 1;28(7):1402-1411. doi: 10.1158/1078-0432.CCR-21-3752. Clin Cancer Res. 2022. PMID: 35046062 Free PMC article.
-
A novel graph convolutional neural network for predicting interaction sites on protein kinase inhibitors in phosphorylation.Sci Rep. 2022 Jan 7;12(1):229. doi: 10.1038/s41598-021-04230-7. Sci Rep. 2022. PMID: 34997142 Free PMC article.
-
Mutation in Abl kinase with altered drug-binding kinetics indicates a novel mechanism of imatinib resistance.Proc Natl Acad Sci U S A. 2021 Nov 16;118(46):e2111451118. doi: 10.1073/pnas.2111451118. Proc Natl Acad Sci U S A. 2021. PMID: 34750265 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
